RA Capital Nexus Fund III, L.P. has an estimated net worth of $61.1 Million. This is based on reported shares across multiple companies, which include Mineralys Therapeutics, Inc., Climb Bio, Inc., Artiva Biotherapeutics, Inc., Bicara Therapeutics Inc., Septerna, Inc., Sionna Therapeutics, Inc., Evommune, Inc., and SpyGlass Pharma, Inc..

2024 was RA Capital Nexus Fund III, L.P.'s most active year for acquiring shares with 24 total transactions. RA Capital Nexus Fund III, L.P.'s most active month to acquire stocks was the month of January. 2025 was RA Capital Nexus Fund III, L.P.'s most active year for disposing of shares, totalling 55 transactions. RA Capital Nexus Fund III, L.P.'s most active month to dispose stocks was the month of October. 2024 saw RA Capital Nexus Fund III, L.P. paying a total of $292,716,020.79 for 44,341,580 shares, this is the most they've acquired in one year. In 2025 RA Capital Nexus Fund III, L.P. cashed out on 32,598,206 shares for a total of $21,463,465.68, their largest year based on trade value.